相关实验视频
Updated: Jul 9, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
Published on: June 21, 2018
基于生理学的sparsentan的药理动力学模型,以评估潜在的药物相互作用
Nikunjkumar K Patel1, Kuan-Fu Chen1, Shang-Chiung Chen2
1Simcyp Division, Certara UK Limited, Sheffield, UK.
斯帕森坦是一种双重内甲素/ ангиотензинII受体对抗剂,当与强大的CYP3A4抑制剂一起服用时,可能会显著增加暴露. 抑制P-葡萄糖蛋白对斯帕森坦的药理动力学影响微不足道.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物新陈代谢 药物新陈代谢
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 斯帕森坦是一种双重内甲素/ ангиотензинII受体对抗剂,用于治疗IgA脏病.
- 实验室研究表明,斯帕森坦可能与CYP酶相互作用.
- 了解药物相互作用 (DDI) 对sparsentan的临床使用至关重要.
研究的目的:
- 评估sparsentan作为CYP3A4中介药物相互作用 (DDI) 的受害者和行为者的潜力.
- 开发和验证一个基于生理学的药理动力学 (PK) 模型,用于sparsentan.
- 预测DDI对斯帕森坦暴露的影响.
主要方法:
- 使用体外数据开发了一个基于生理学的药理动力学 (PK) 模型.
- 该模型与临床PK数据和模拟的DDI进行了验证.
- 模拟研究了斯帕森坦作为CYP3A4,CYP2C9和CYP2C19的事者和受害者以及P-糖蛋白 (P-gp) 抑制的相互作用.
主要成果:
- 如果使用强大的CYP3A4抑制剂 (例如伊特拉可纳),斯帕森坦的暴露可能会增加两倍以上.
- 其他潜在的受害者或事者DDI互动在两倍变化范围内.
- 完全抑制P-gp对sparsentan的PK的影响是微不足道的.
结论:
- 斯帕森坦对DDI具有显著的潜力,特别是作为CYP3A4抑制的受害者.
- 开发的 PK 模型为预测 sparsentan DDI 提供了一个有价值的工具.
- 建议在与强大的CYP3A4抑制剂同时服用斯帕森坦时进行临床监测.
更多相关视频
00:05A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
Published on: August 27, 2019
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
相关概念视频
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Model Approaches for Pharmacokinetic Data: Physiological Models
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Physiological Pharmacokinetic Models: Assumption with Protein Binding
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...